Myeloproliferative Neoplasms | Topics

Differences Between Types of Myelofibrosis
June 27, 2022

Aaron Gerds, MD, explains the various types of myelofibrosis and the underlying pathophysiologies.

Diagnosis and Risk Stratification of Myelofibrosis
June 27, 2022

Srdan Verstovsek, MD, PhD, provides an overview of how myelofibrosis is diagnosed and what criteria are used for risk stratification.

Navitoclax Plus Ruxolitinib Combo Elicits Responses Indicative of Myelofibrosis Disease Modification
April 12, 2022

Bone marrow fibrosis improvement and variant allele frequency reduction observed with navitoclax plus ruxolitinib for patients with previously treated myelofibrosis may suggest disease modification.

Advances in the Treatment of Myelofibrosis
March 13, 2022

John Mascarenhas, MD, hosts a panel of experts who discusses current strategies used to stratify risk patients with myelofibrosis and their preferences for sequencing therapy.

Mesa Considers Next Steps With Pacritinib in Myelofibrosis
March 04, 2022

Ruben Mesa, MD, spoke about why pacritinib in the treatment of myelofibrosis is beneficial.

Mesa Talks Benefits of Pacritinib in Myelofibrosis With Marked Thrombocytopenia
March 02, 2022

Ruben Mesa, MD, spoke about which patients stand to benefit the most from the approval of pacritinib in myelofibrosis with severe thrombocytopenia.

Pacritinib Granted Accelerated Approval for Use in Myelofibrosis With Severe Thrombocytopenia
March 01, 2022

Patients with intermediate- or high-risk primary or secondary myelofibrosis with a low platelet count may derive benefit from treatment with pacritinib following its accelerated approval by the FDA.

Mesa Discusses Importance of Pacritinib Accelerated Approval for Myelofibrosis With Severe Thrombocytopenia
March 01, 2022

Ruben Mesa, MD, spoke about the accelerated approval of pacritinib and its importance for the treatment of myelofibrosis with severe thrombocytopenia.

Momelotinib Yields Statistically Significant Improvement in Symptoms for Myelofibrosis
January 27, 2022

Topline findings from the phase 3 MOMENTUM study indicated that patients with myelofibrosis experienced a statistically significant reduction in symptoms following treatment with momelotinib.

Mesa Gives an Overview of Myelofibrosis in 2021
January 15, 2022

At ASH 2021, CancerNetwork® spoke with Ruben Mesa, MD, of UT Health San Antonio MD Anderson Cancer Center, about key takeaways learned in the treatment of myelofibrosis during 2021.